Abbott To Develop New Heart Failure Test On ARCHITECT® Immunochemistry Diagnostics Platform

Abbott (NYSE: ABT) and BG Medicine, Inc. announced a development and commercialization agreement for galectin-3, a novel biomarker that may play a role in detecting the development and progression of heart failure. The assay will be developed for Abbott’s ARCHITECT immunochemistry instrument platform, specifically the company’s i1000SR and i2000SR instruments.

Go to Source

People who read this also read

• Ambry Genetics Launches First X-Linked Mental Retardation Diagnostics Using Next Generation Sequencing
  Ambry Genetics today introduced The Ambry X-Linked Mental Retardation SuperPANEL™, a suite of genetic tests expected to pinpoint the cause of intellectual disability and X-linked mental retardation (XLMR). This panel marks the first time next generation sequencing technology, coupled with microarra...
• BD Diagnostics Launches The BD Protect(TM) Infection Surveillance And Prevention Software Portfolio
  BD Diagnostics, a segment of BD (Becton, Dickinson and Company), announced the launch of the BD Protect™ Infection Surveillance and Data Management System, a portfolio of healthcare management software solutions that tracks infections and helps prevent their transmission at three levels -- from pati...
• NVIDIA Tesla GPUs Help TechniScan Deliver Timely Breast Imaging Diagnostics
  TechniScan, Inc. (OTC Bulletin Board: TSNI) is featured on NVIDIA's recently posted blog about speeding the amount of time it takes to get breast imaging results into the hands of doctors and patients. NVIDIA is the world leader in visual computing technologies and inventor of the graphics processi...
• In Cancer Diagnostics, The Profit Is In Test Services
  The majority of new cancer tests coming to market are proprietary assays with the test services being provided by certified labs opened by the IVD companies that developed the tests. All the major reference labs in North America and Europe are also offering a slew of in-house developed diagnostic te...
• Predictive Biosciences To Present Novel Combination Approach To Molecular Cancer Diagnostics At 2010 Genitourinary Cancers Symposium
  Predictive Biosciences announced that the Company will be presenting its novel Multi-Analyte Diagnostic Readout (MADR™) approach to the development of a non-invasive, urinary biomarker based assay for the detection of bladder cancer during the 2010 Genitourinary Cancers Symposium (GU Symposium), bei...